Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rotmensch

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Gynecologic Oncology|September 5, 2001
Outcome of endometrial carcinoma patients with involvement of the uterine serosaJ B Ashman, P P Connell, D Yamada, et al.
Analytical and Quantitative Cytology and Histology|October 1, 1989
Characterization of a human ovarian carcinomaJ Rotmensch, J L Schwartz, M A Beckett, et al.
Gynecologic Oncology|December 1, 1989
The inherent cellular radiosensitivity of epithelial ovarian carcinomaJ Rotmensch, J L Schwartz, R W Atcher, et al.
Environmental and Molecular Mutagenesis|January 1, 1990
Comparison of radon-daughter-induced effects in repair-proficient and repair-deficient CHO cell linesJ L Schwartz, J D Shadley, R W Atcher, et al.
Mutagenesis|November 1, 1994
Multiplex polymerase chain reaction-based deletion analysis of spontaneous, gamma ray- and alpha-induced hprt mutants of CHO-K1 cellsJ L Schwartz, J Rotmensch, J Sun, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2001
Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinomaA J Mundt, K T Murphy, J Rotmensch, et al.
American Journal of Obstetrics and Gynecology|April 1, 1997
In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinomaJ Rotmensch, J L Whitlock, J L Schwartz, et al.
The Journal of Reproductive Medicine|July 1, 1994
CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disordersM A Ismail, J Rotmensch, L J Mercer, et al.
American Journal of Obstetrics and Gynecology|April 1, 1989
The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinomaJ Rotmensch, R W Atcher, J Hines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2002
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumorsC Eng, A M Mauer, G F Fleming, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Gynecologic Oncology|September 5, 2001
Outcome of endometrial carcinoma patients with involvement of the uterine serosaJ B Ashman, P P Connell, D Yamada, et al.
Analytical and Quantitative Cytology and Histology|October 1, 1989
Characterization of a human ovarian carcinomaJ Rotmensch, J L Schwartz, M A Beckett, et al.
Gynecologic Oncology|December 1, 1989
The inherent cellular radiosensitivity of epithelial ovarian carcinomaJ Rotmensch, J L Schwartz, R W Atcher, et al.
Environmental and Molecular Mutagenesis|January 1, 1990
Comparison of radon-daughter-induced effects in repair-proficient and repair-deficient CHO cell linesJ L Schwartz, J D Shadley, R W Atcher, et al.
Mutagenesis|November 1, 1994
Multiplex polymerase chain reaction-based deletion analysis of spontaneous, gamma ray- and alpha-induced hprt mutants of CHO-K1 cellsJ L Schwartz, J Rotmensch, J Sun, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2001
Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinomaA J Mundt, K T Murphy, J Rotmensch, et al.
American Journal of Obstetrics and Gynecology|April 1, 1997
In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinomaJ Rotmensch, J L Whitlock, J L Schwartz, et al.
The Journal of Reproductive Medicine|July 1, 1994
CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disordersM A Ismail, J Rotmensch, L J Mercer, et al.
American Journal of Obstetrics and Gynecology|April 1, 1989
The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinomaJ Rotmensch, R W Atcher, J Hines, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2002
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumorsC Eng, A M Mauer, G F Fleming, et al.
Pageof 8